simvastatin产品活性：simvastatin 是一种竞争性的 hmg-coa reductase 抑制剂，ki 值为 0.2 nm。
研究领域：metabolic enzyme/protease | autophagy
作用靶点：hmg-coa reductase (hmgcr) | autophagy | mitophagy
in vitro: simvastatin needs to be activated by naoh in etoh treatment before use for cell assay. simvastatin suppresses cholesterol synthesis in mouse l-m cell, rat h4ii e cell, and human hep g2 cell with ic50s of 19.3 nm, 13.3 nm and 15.6 nm, respectively. simvastatin causes a dose-dependent increase in serine 473 phosphorylation of akt within 30 minutes, with maximal phosphorylation occurring at 1.0 µm. simvastatin (1.0 μm) enhances phosphorylation of the endogenous akt substrate endothelial nitric oxide synthase (enos), inhibits serum-free media undergo apoptosis and accelerates vascular structure formation. simvastatin shows anti-inflammatory effects, reduces anti-cd3/anti-cd28 antibody-stimulated proliferation of pb-derived mononuclear cells and synovial fluid cells from rheumatoid arthritis blood, as well as ifn-γ release at 10 μm. simvastatin (10 μm) also blocks cell-mediated macrophage tnf-γ release induced via cognate interactions by appr 30%. simvastatin (5 μm) significantly reduces the expression of abca1 in astrocytes and neuroblastoma cells, the expression of apolipoprotein e in astrocytes, and increases cyclin-dependent kinase 5 and glycogen synthase kinase 3β expression in sk-n-sh cells.
in vivo: simvastatin suppresses the conversion of radiolabeled acetate to cholesterol with an ic50 of 0.2 mg/kg via p.o. administration. simvastatin (4 mg/day, p.o. for 13 weeks) returns the cholesterol-induced increases in total cholesterol, ldl-cholesterol and hdl-cholesterol to normal level in rabbits fed an atherogenci cholesterol-rich diet. simvastatin (6 mg/kg) increases ldl receptor-dependent binding and the number of hepatic ldl receptors in rabbits fed a diet containing 0.25% cholesterol. simvastatin affects inflammation independent of its effect on plasma cholesterol level. simvastatin (20 mg/kg/day) causes a 1.3-fold less macrophage content in lesions, and 2-fold less vascular cell adhesion molecule-1, interleukin-1beta, and tissue factor expression, companied by a 2.1-fold increases in lesional smooth muscle cell and collagen content in cynomolgus monkeys fed an atherogenic diet.
相关产品：fda-approved drug library plus | drug repurposing compound library | fda-approved drug library mini | anti-aging compound library | covalent screening library | cns-penetrant compound library | fda-approved drug library | metabolism/protease compound library | drug repurposing compound library plus | bioactive compound library plus | autophagy compound library | 3-methyladenine | olaparib | doxorubicin hydrochloride | sb 203580 | u0126 | metformin hydrochloride | aicar | brefeldin a | dexamethasone | ruxolitinib | etoposide | vorinostat | deferoxamine mesylate | tanespimycin | resveratrol | curcumin | melatonin | sunitinib | abt-737 | quercetin | salinomycin | valproic acid | lovastatin | hemin | atorvastatin hemicalcium salt | tripterin | aspirin | oxidopamine hydrobromide | rosuvastatin calcium
MedChemExpress LLC
郑先生
86-021-58955995
17321200539